Neuronetics announces FDA clearance for NeuroStar add-on therapy for ages 15 and older

Neuronetics, Inc.

FDA cleared NeuroStar Advanced Therapy System as an add-on treatment for patients aged 15 and older.
Management targets cash flow break-even in Q4 2024 and on a full-year basis in 2025.
Proposed combination with Greenbrook TMS Inc. remains ongoing; stockholder approval pending.
Company presenting at William Blair 44th Annual Growth Stock Conference on August 14, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.